Life Science Platform Promotes True Scientific Collaboration

SyynX Solutions GmbHCollexis (OTCBB: CLXS), a leading developer of high-definition search and discovery software, and their German partner, SyynX Solutions, announced they will preview a new life sciences social networking site to representatives from global book publishing and multimedia companies at the Frankfurt Book Fair in Frankfurt, Germany. This online community represents the next generation in social networks. The comprehensive system of pre-populated expert profiles, coupled with the ability to analyze all associated professional connections within the network, allows scientists and researchers across multiple organizations to share data and collaborate in ways never before considered.

Over the next few weeks, a controlled group of research thought leaders are testing the site for a public launch slated for January, when the site's name and web address will be formally released to the public. However, Frankfurt Book Fair attendees can gain access to the site at the companies' joint booth, number 417 in Hall 4.2, at any time during the conference.

Designed to promote collaborative research and development in advancing medical science, the site is the first social networking application to incorporate pre-generated expert profiles of over 1.4 million biomedical experts from more than 150 countries. It currently houses approximately 12 million pre-established network connections, automatically generated from over six million scientific publications from 6,500 journals. Contrary to the first generation social networks like Facebook and LinkedIn, this life science open platform goes to the next level and reflects the real-life activity network of the experts worldwide.

"Social networking isn't just for teenagers. There are a growing number of academics who are finding that online communities are the perfect way to share, collaborate and discuss their work," said Bill Kirkland, Collexis CEO. "But until now, an efficient way to coordinate the abundance of available digital information did not exist. The technology behind our site now makes it possible for researchers to collaborate in a way not previously possible."

"When a researcher logs into the site, available at no-charge, they will immediately see a robust synopsis of their publications, interests and network," added Kirkland. "The depth of this information, encompassing almost every published researcher in the biomedical sciences field worldwide, is what makes the site incredibly powerful. It also serves as a definitive source to identify relationships to others within the community, either by topic or geography."

The social networking site is based on Collexis' proprietary Fingerprint technology, a valuable research tool already employed by organizations such as: Johns Hopkins, The Mayo Clinic, Harvard University and The National Institute of Health.

"Taking the Collexis technology, which has become the platform of choice for leading biomedical companies, and combining it with a free social network application was really the next logical step," said Christian Herzog, MD, CEO of SyynX Solutions. "Thanks to the genius of Martin Schmidt, our chief technology officer, in collaboration with the Collexis leadership, the research community will now be able to instantaneously identify relevant expertise in a specific research area and start collaborating directly. Plus, we see the next generations of this platform expanding beyond biomedical research and into larger, global R&D development efforts."

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of High Definition Search and Discovery software since 1999, is headquartered in Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The Netherlands. Collexis proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis shares of common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, please visit www.collexis.com.

About SyynX Solutions GmbH
SyynX Solutions GmbH is a German software company which focuses on text mining based applications for the areas of life science and health care. Collexis and SyynX are already co-operating closely since almost ten years on the technical and commercial level. The SyynX applications based on the Collexis fingerprint technology are used by customers like universities, pharmaceutical and biotech companies around the world. The text mining applications like the SyynX Knowledge Dashboard helps the user to analyze large text corpora without applying standard search approaches and provides him automatically with expert profiles, trends and knowledge discovery routines. For more information please visit www.syynx.de.

Most Popular Now

AI also Assesses Dutch Mammograms Better…

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by...

RSNA AI Challenge Models can Independent…

Algorithms submitted for an AI Challenge hosted by the Radiological Society of North America (RSNA) have shown excellent performance for detecting breast cancers on mammography images, increasing screening sensitivity while...

AI could Help Emergency Rooms Predict Ad…

Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study by the...

Head-to-Head Against AI, Pharmacy Studen…

Students pursuing a Doctor of Pharmacy degree routinely take - and pass - rigorous exams to prove competency in several areas. Can ChatGPT accurately answer the same questions? A new...

NHS Active 10 Walking Tracker Users are …

Users of the NHS Active 10 app, designed to encourage people to become more active, immediately increased their amount of brisk and non-brisk walking upon using the app, according to...

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...